Semler Scientific, Inc. (OTCMKTS:SMLR) CEO Douglas Murphy-Chutorian sold 1,250 shares of the stock in a transaction that occurred on Monday, October 11th. The shares were sold at an average price of $129.01, for a total value of $161,262.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Douglas Murphy-Chutorian also recently made the following trade(s):
- On Monday, October 4th, Douglas Murphy-Chutorian sold 1,250 shares of Semler Scientific stock. The shares were sold at an average price of $127.28, for a total value of $159,100.00.
OTCMKTS:SMLR traded up $3.65 during trading hours on Wednesday, hitting $136.65. The company’s stock had a trading volume of 83,744 shares, compared to its average volume of 15,260. The business’s 50-day moving average is $114.62 and its two-hundred day moving average is $112.95. The company has a market capitalization of $922.93 million, a PE ratio of 50.61, a PEG ratio of 1.52 and a beta of 0.85. Semler Scientific, Inc. has a 52-week low of $52.90 and a 52-week high of $144.87.
SMLR has been the subject of several recent research reports. Lake Street Capital increased their price target on Semler Scientific from $150.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 28th. B. Riley reaffirmed a “buy” rating and set a $151.00 price target on shares of Semler Scientific in a report on Wednesday, August 4th. Colliers Securities reaffirmed an “average” rating and set a $151.00 price target on shares of Semler Scientific in a report on Tuesday, September 28th. TheStreet raised Semler Scientific from a “d-” rating to an “a-” rating in a report on Tuesday, September 28th. Finally, Zacks Investment Research downgraded Semler Scientific from a “buy” rating to a “hold” rating in a report on Thursday, October 7th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Semler Scientific currently has an average rating of “Buy” and a consensus price target of $157.75.
About Semler Scientific
Semler Scientific, Inc engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests.
Featured Story: Strangles
Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.